原发性乳腺浸润性导管癌组织中生长抑素受体表达及其意义

目的：研究生长抑素受体（SSTR）在原发性乳腺浸润性癌组织中的表达情况，以及与临床病理因素的关系。方法：应用免疫组化法检测82例原发性乳腺浸润性导管癌组织中SSTR的表达，分析其与临床病理因素的关系。结果：原发性乳腺浸润性导管癌组织中SSTR阳性表达率为74．4％（61／82）。SSTR阳性表达强度与年龄（P=0．881）、肿瘤大小（P=0．522）无关，但不同病理分期（P〈0．001）、分化程度（P=0．021）的肿瘤组织其SSTR表达强度有显著性差异。结论：原发性乳腺浸润性导管癌组织中SSTR阳性表达率为74．4％，因此，对大多数疑为乳腺癌的患者可应用核素显像技术（SRS）进行筛选。

Expression of somatostatin receptor in primary invasive ductal carcinoma of breast

Objective: To determinate whether human primary breast invasive ductal carcinoma((HPBIDC)) express somatostatin receptor(SSTR). Methods: SSTR expression in 82 patients with invasive duct carcinoma of breast was determined by immunohistochemistry and its correlation with clinical and pathological facts was analysed. Results: IHC analyses revealed that SSTR was expressed in HPBIDC (61/82, 74.4%). A significant correlation was found between SSTR expression and tumor stage (P<0.001), tumor differentiation (P<0.021), and there are no statistically significant relationship between the expression of SSTR and the age(P=0.881), and the tumor size (P=0.522). Conclusion: SSTR expression ratio in invasive ductal carcinoma of breast is 74.4% (61/82).